Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab

Biochemical and Biophysical Research Communications

Volumn 375, Issue 4, 2008, Pages 619-622

  Zheng, Lei ^a,b   Li, Bohua ^b,c   Qian, Weizhu ^b,c   Zhao, Lei ^b   Cao, Zhiguo ^b   Shi, Shu ^b   Gao, Jie ^b   Zhang, Dapeng ^b,c   Hou, Sheng ^b,c   Dai, Jianxin ^b,c   Wang, Hao ^b,c   Guo, Yajun ^a,b,c  

^a SICHUAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c National Engineering Research Center for Antibody Medicine   (China)

Author keywords

Epitope; IgE; Monoclonal antibody; Omalizumab; Phage display peptide library

Indexed keywords

HISTIDYLLEUCYLPROLINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB; PEPTIDE; PEPTIDE LIBRARY; THREONYLHISTIDYLPROLYLHISTIDYLLEUCYLPROLYLARGINYLALANYLLEUCYLMETHIONYL ARGINYLSERINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; DRUG BINDING; DRUG MECHANISM; EPITOPE MAPPING; HUMAN; HUMAN CELL; PHAGE DISPLAY; PRIORITY JOURNAL;

AMINO ACID MOTIFS; ANTIBODIES, MONOCLONAL; EPITOPE MAPPING; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FC FRAGMENTS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN CONFORMATION;

EID: 51449106743     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.08.055     Document Type: Article

References (17)

1. Lundbäck B. Epidemiology of rhinitis and asthma. Clin. Exp. Allergy 28 (1998) 3-10
2. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 18 (2000) 157-162
3. Metzger H., Alcaraz G., Hohman R., Kinet J.P., Pribluda V., and Quarto R. The receptor with high affinity for immunoglobulin E. Annu. Rev. Immunol. 4 (1986) 419-470
4. Davis F.M., Gossett L.A., Pinkston K.L., Liou R.S., Sun L.K., Kim Y.W., Chang N.T., Chang T.W., Wagner K., Bews J., Brinkmann V., Towbin H., Subramanian N., and Heusser C. Can anti-IgE be used to treat allergy?. Springer Semin. Immunopathol. 15 (1993) 51-73
5. Garman S.C., Wurzburg B.A., Tarchevskaya S.S., Kinet J.P., and Jardetzky T.S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 406 (2000) 259-266
6. Gould H.J., and Sutton B.J. IgE in allergy and asthma today. Nat. Rev. Immunol. 8 (2008) 205-217
7. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., and Jardieu P.M. Humanization of an antibody directed against IgE. J. Immunol. 151 (1993) 2623-2632
8. D'Amato G., Salzillo A., Piccolo A., D'Amato M., and Liccardi G. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma. Ther. Clin. Risk Manag. 3 (2007) 613-619
9. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir. Med. 100 (2006) 1907-1917
10. Owen C.E. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic. Pharmacol. Ther. 113 (2007) 121-133
11. Perosa F., Favoino E., Caragnano M.A., and Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107 (2006) 1070-1077
12. Binder M., Vögtle F.N., Michelfelder S., Müller F., Illerhaus G., Sundararajan S., Mertelsmann R., and Trepel M. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 67 (2007) 3518-3523
13. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J. Allergy Clin. Immunol. 114 (2004) 527-530
14. Lin H., Boesel K.M., Griffith D.T., Prussin C., Foster B., Romero F.A., Townley R., and Casale T.B. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J. Allergy Clin. Immunol. 113 (2004) 297-302
15. Saini S.S., MacGlashan Jr. D.W., Sterbinsky S.A., Togias A., Adelman D.C., Lichtenstein L.M., and Bochner B.S. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J. Immunol. 162 (1999) 5624-5630
16. Feuchtinger T., Bartz H., von Berg A., Riedinger F., Brauburger J., Stenglein S., Wahn U., and Schauer U. Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. J. Allergy Clin. Immunol. 111 (2003) 428-430
17. Prussin C., Griffith D.T., Boesel K.M., Lin H., Foster B., and Casale T.B. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J. Allergy Clin. Immunol. 112 (2003) 1147-1154